HC Wainwright & Co. Reiterates Buy on Medicenna Therapeutics, Maintains $2.5 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a 'Buy' rating on Medicenna Therapeutics (NASDAQ:MDNA) and maintained a price target of $2.5.

August 10, 2023 | 10:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Medicenna Therapeutics has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $2.5.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates their continued confidence in Medicenna Therapeutics. This could potentially attract more investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100